← Back to patent-cliff list
Ezetimibe/Rosuvastatin Calcium/Candesartan Cilexetil/Amlodipine
Tier C — Watch / tradeEzetimibe/Rosuvastatin Calcium/Candesartan Cilexetil/Amlodipine
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NPC1L1, HMGCR, AT1, VDCCs
Indications (approved)：Hyperlipoproteinaemia type II, Hypertension
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ezetimibe/Rosuvastatin Calcium/Candesartan Cilexetil/Amlodipine?
Approved indications include: Hyperlipoproteinaemia type II, Hypertension.
When does the Ezetimibe/Rosuvastatin Calcium/Candesartan Cilexetil/Amlodipine patent expire?
No public expiry year is available for Ezetimibe/Rosuvastatin Calcium/Candesartan Cilexetil/Amlodipine yet; this page updates once verified.
How do I get a quote for Ezetimibe/Rosuvastatin Calcium/Candesartan Cilexetil/Amlodipine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30